Anti-Diabetes Drugs - Lesotho | Statista Market Forecast

The Anti-Diabetes Drugs market in Lesotho is expected to witness significant growth in the coming years.
According to projections, the revenue for this market is estimated to reach US$2.35m units by 2024.
Furthermore, it is anticipated to exhibit an impressive compound annual growth rate (CAGR 2024-2029) of 7.50%.
This positive trend is expected to result in a market volume of US$3.38m units by 2029.
When compared globally, United States is projected to generate the highest revenue in the Anti-Diabetes Drugs market.
In 2024, the revenue United States is anticipated to reach a staggering US$37.84bn units.
Lesotho is experiencing a growing demand for anti-diabetes drugs due to the high prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Lesotho has been developing at a steady pace in recent years.

Customer preferences: The demand for Anti-Diabetes Drugs in Lesotho has been increasing due to the rising prevalence of diabetes among the population. The majority of the population in Lesotho lives in rural areas, where access to healthcare facilities is limited. As a result, many people with diabetes rely on medication to manage their condition.

Trends in the market: The Anti-Diabetes Drugs market in Lesotho has been growing due to the increasing prevalence of diabetes in the country. The market is dominated by multinational pharmaceutical companies that offer a range of products to treat diabetes. The market is also characterized by the availability of generic drugs, which are often cheaper than branded drugs. However, the quality of generic drugs is often a concern for patients.

Local special circumstances: Lesotho is a small, landlocked country in Southern Africa with a population of approximately 2 million people. The country has a high prevalence of diabetes, with an estimated 10% of the population affected by the disease. The healthcare system in Lesotho is under-resourced, and access to healthcare services is limited, particularly in rural areas.

Underlying macroeconomic factors: The economy of Lesotho is heavily dependent on agriculture, with the majority of the population engaged in subsistence farming. The country is also highly dependent on foreign aid, which accounts for a significant proportion of government revenue. The high prevalence of diabetes in Lesotho is a major public health concern, and the government has implemented a number of measures to address the issue, including the provision of free diabetes medication to patients. However, the availability and affordability of medication remain major challenges in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.